Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSD on Neuroplasticity in Healthy Subjects
NCT05177419Phase 1Completed
- Sponsor
- University of Fribourg
- Start
- May 2022
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lysergide in major depressive disorder (MDD), anxiety disorder and addictive disorders (2 arms), sponsored by University of Fribourg. Primary endpoint: Change in motor evoked potential amplitude after paired associative stimulation at 1 week. Started May 2022; status: completed.
02
Drugs
Lysergide
03
Conditions
major depressive disorder (MDD)anxiety disorderaddictive disorders
Beyond the preview
Go deeper on NCT05177419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177419.